@article{2ac52dcfd20d469199a363ef768c58e2,
title = "Alzheimer's disease and other dementias: Advances in 2014",
author = "Randall Bateman",
note = "Funding Information: I declare grants from Alzheimer's Association, American Academy of Neurology, Anonymous Foundation, AstraZeneca, BrightFocus Foundation, Cure Alzheimer's Fund, Glenn Foundation for Medical Research, Merck Lilly, Metropolitan Life Foundation, National Institutes of Health and National Institute on Aging, DIAN Pharma Consortium Pharma Consortium (Biogen Idec, Elan Pharmaceuticals, Eli Lilly and Co, Hoffman La-Roche, Genentech, Janssen Alzheimer Immunotherapy, Mithridion, Novartis Pharma AG, Pfizer Biotherapeutics R and D, Sanofi-Aventi, and Eisai), Roche, Ruth K Broadman Biomedical Research Foundation; non-financial support from Avid Radiopharmaceuticals Cogstate; a role as co-founder and part owner of C2N Diagnostics; subcontract fees as the site principle investigator for the A4 Trial from NIH and state government sources; personal fees, employment and intellectual property rights (patent co-inventor) from Washington University (MO, USA); personal fees and non-financial support from Roche, Innovative Medicines Initiative, Sanofi, Global Alzheimer's Platform, FORUM, Organisation for Economic Co-operation and Development, and Boehringer Ingelheim; and personal fees from Merck; all outside the submitted work. ",
year = "2015",
month = jan,
day = "1",
doi = "10.1016/S1474-4422(14)70301-1",
language = "English",
volume = "14",
pages = "4--6",
journal = "The Lancet Neurology",
issn = "1474-4422",
number = "1",
}